Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Various

Thumbnail
March 01, 2021

US FDA approval tracker February

Thumbnail
March 01, 2021

Go or no go? A delayed decision on Evrenzo

March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.

Article image
Vantage logo
February 02, 2021

US FDA approval tracker: January

Article image
Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.

Article image
Vantage logo
January 06, 2021

US FDA approval tracker: December

Article image
Vantage logo
December 23, 2020

Go or no go? New Year approval decisions for the US regulators

Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.

Article image
Vantage logo
December 23, 2020

Voyager hold adds to gene therapy woes

Article image
Vantage logo
December 18, 2020

First-quarter catalysts for the smaller players

Important data releases are on the cards for Rhythm, Wave and Supernus, among others.

Article image
Vantage logo
December 17, 2020

Key upcoming clinical catalysts for biotech

Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.

Article image
Vantage logo
December 15, 2020

Big pharma catalysts to ring in the new year

Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.

Article image
Vantage logo
December 02, 2020

US FDA approval tracker: November

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.